Alliance Global Partners analyst James Molloy initiated coverage of GeoVax Labs (GOVX) with a Buy rating and $15 price target Lead candidate GEO-CM04S1 is a “potentially best-in-class” COVID-19 prophylactic with potential in both healthy and immunocompromised patients, notes the analyst, who attributes $12.25 per share in value to CMO4S1. The firm also attributes $2 per share in value to Gedeptin, a head and neck cancer injectable therapeutic that the company is also advancing, along with cash and the remaining technology being valued at 75c per share.
Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter